These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32436085)

  • 1. A Trinity regimen with aflibercept for treatment-naïve neovascular age-related macular degeneration: 2-year outcomes.
    Wakuta M; Nomi N; Ogata T; Ota M; Yamashiro C; Hatano M; Yanai R; Tokuda K; Kimura K
    Graefes Arch Clin Exp Ophthalmol; 2020 Aug; 258(8):1663-1670. PubMed ID: 32436085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
    Kvannli L; Krohn J
    Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.
    Augsburger M; Sarra GM; Imesch P
    Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1889-1895. PubMed ID: 31256237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration.
    Aurell S; Sjövall K; Paul A; Morén Å; Granstam E
    Acta Ophthalmol; 2019 Aug; 97(5):519-524. PubMed ID: 30511374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration.
    Ohnaka M; Nagai Y; Sho K; Miki K; Kimura M; Chihara T; Takahashi K
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):657-664. PubMed ID: 27743159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.
    Maruko I; Ogasawara M; Yamamoto A; Itagaki K; Hasegawa T; Arakawa H; Nakayama M; Koizumi H; Okada AA; Sekiryu T; Iida T
    Ophthalmol Retina; 2020 Aug; 4(8):767-776. PubMed ID: 32417356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of Switching from Pro Re Nata to Treat-and-Extend Regimen in Treatment of Patients with Type 3 Neovascularization.
    Kim JH
    Semin Ophthalmol; 2020 Jan; 35(1):33-40. PubMed ID: 31814497
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TWELVE-MONTH OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fixed Versus As-needed Dosing.
    Veritti D; Sarao V; Missiroli F; Ricci F; Lanzetta P
    Retina; 2019 Nov; 39(11):2077-2083. PubMed ID: 30161093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration.
    Haga A; Kawaji T; Ideta R; Inomata Y; Tanihara H
    Acta Ophthalmol; 2018 May; 96(3):e393-e398. PubMed ID: 29220114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pro re nata versus Bimonthly Injection of Intravitreal Aflibercept for Typical Neovascular Age-Related Macular Degeneration.
    Mori R; Tanaka K; Haruyama M; Kawamura A; Furuya K; Yuzawa M
    Ophthalmologica; 2017; 238(1-2):17-22. PubMed ID: 28402983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
    Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.
    Ricci F; Parravano M; Regine F; Sciamanna M; Tedeschi M; Missiroli F; Varano M
    Eye (Lond); 2016 Aug; 30(8):1077-83. PubMed ID: 27229701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
    Muftuoglu IK; Arcinue CA; Tsai FF; Alam M; Gaber R; Camacho N; You Q; Freeman WR
    Am J Ophthalmol; 2016 Jul; 167():1-9. PubMed ID: 27049000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-Year Outcomes of a Treat-and-Extend Regimen Using Intravitreal Aflibercept Injections for Typical Age-Related Macular Degeneration.
    Ito A; Matsumoto H; Morimoto M; Mimura K; Akiyama H
    Ophthalmologica; 2017; 238(4):236-242. PubMed ID: 28898873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.
    Feltgen N; Bertelmann T; Bretag M; Pfeiffer S; Hilgers R; Callizo J; Goldammer L; Bemme S; Hoerauf H
    Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):923-934. PubMed ID: 28102456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
    Blanco-Garavito R; Jung C; Uzzan J; Quaranta-ElMaftouhi M; Coscas F; Sahel J; Korobelnik JF; Béchet S; Querques G; Souied EH
    Retina; 2018 Dec; 38(12):2285-2292. PubMed ID: 29190241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
    Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
    Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.
    Elwes F; Borooah S; Aspinall P; Sim PY; Loo CY; Armbrecht AM; Dhillon B; Cackett P
    BMC Ophthalmol; 2018 Jan; 18(1):20. PubMed ID: 29378528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.